The EU Medical Device Regulation and its in-vitro diagnostic counterpart both require that the information supplied with a device, meaning the instructions for use and the labelling, is available in the official language or languages determined by each member state where the device is made available. Member states set their own requirements, and most require their own official language.

Sell across the union and the practical consequence is that documentation can be obliged in up to 24 languages. Not as a marketing preference. As a condition of the product being placed on the market.

Why this is an operations problem rather than a translation one

A single translation project is finite. This is not. Three things make the obligation recur:

  • Product revisions. Change the device, change the IFU, and every language version has to follow. Anything that lags is a version mismatch in a regulated document.
  • Regulatory updates. Guidance changes, harmonised standards move, and content that was compliant last year quietly is not.
  • Market expansion. Each additional member state can add a language, and the existing corpus has to be extended into it consistently rather than translated afresh.

Managed as a series of projects, the cost is roughly linear and the terminology drifts. Managed as a programme with maintained translation memory and a controlled term base, cost falls with each revision because the unchanged content is already translated, approved and reusable.

The terminology exposure most teams underestimate

In regulated documentation the risk is rarely a mistranslated sentence. It is the same term rendered three different ways across an IFU, a label and a technical file, because three suppliers translated them in three quarters without a shared term base. That inconsistency is exactly what an auditor notices, and it is entirely preventable at the operations layer.

What good looks like

  • One controlled term base per product family, maintained centrally and enforced across every supplier and language
  • Translation memory partitioned by document type, so leverage figures are honest rather than inflated
  • Linguists with demonstrable medical competence, with review by a second qualified pair of eyes
  • A retained audit trail showing who translated, who reviewed and against which approved terminology
  • A change process that propagates a revision into every language version rather than the ones somebody remembered

The commercial framing

Because the obligation attaches to market access, this is not discretionary marketing spend competing with a campaign budget. It is a compliance line item attached to revenue in a specific territory. The useful internal question is not what translation costs, but which markets the company cannot currently place product into, and what that is worth.

This is a summary written for planning purposes and is not legal or regulatory advice. Language obligations vary by member state and by product classification, and you should confirm requirements for your specific case with your regulatory affairs function or notified body.